Clinical Trials SuccessThe Phase 2 study of VT1953 met its primary and secondary endpoints in treating malignant fungating wounds, positioning the program to advance to a pivotal study.
Financial StabilityVyome Holdings has a low burn rate and sufficient cash runway into 2027, providing financial stability for further development.
Market OpportunityMalignant fungating wounds represent a potential market opportunity of over $1 billion with no FDA-approved therapies currently available.